Glenn Tilton - AbbVie Independent Director

ABBV -- USA Stock  

USD 85.80  1.04  1.23%

  Director
Mr. Glenn Fletcher Tilton is the Lead Independent Director of the Company. Mr. Tilton was chairman of the Midwest for JPMorgan Chase Co. from 2011 until his retirement in 2014. From October 2010 to December 2012, Mr. Tilton also served as the nonexecutive chairman of the board of United Continental Holdings, Inc. From September 2002 to October 2010, he served as chairman, president and chief executive officer of UAL Corporationrationration, and chairman and chief executive officer of United Air Lines, Inc., its wholly owned subsidiary. Prior to becoming the vice chairman of Chevron Texaco following the merger of Texaco Inc. and Chevron Corporationration, Mr. Tilton enjoyed a 30year multidisciplinary career with Texaco Inc., culminating in his election as chairman and chief executive officer. Mr. Tilton is also a director of Abbott Laboratories and Phillips 66. Mr. Tilton also served on the board of directors of Lincoln National Corporationrationration from 2002 to 2007, of TXU Corporationrationration from 2005 to 2007, of Corning Incorporated from 2010 to 2012, and of United Continental Holdings, Inc. from 2010 to 2012.
Age: 68  Director Since 2013      
847-932-7900  http://www.abbvie.com

Glenn Tilton Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 10.93 % which means that it generated profit of $10.93 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 401.75 % meaning that it created $401.75 on every $100 dollars invested by stockholders.
The company currently holds 41.22B in liabilities. AbbVie has Current Ratio of 1.18 suggesting that it is in a questionable position to pay out its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Genroku SugiyamaHutchison China MediTech Limite
2013
Karen FerranteHutchison China MediTech Limite
2017
Suzanne JohnsonPfizer
2007
Stephen SangerPfizer
2009
Alan LacyBristol Myers Squibb Company
2008
Akihiko HiraokaHutchison China MediTech Limite
2015
Helen HobbsPfizer
2011
Tsutomu MizutaniHutchison China MediTech Limite
2015
James KiltsPfizer
2007
Theodore SamuelsBristol Myers Squibb Company
2017
Jamere JacksonEli Lilly and Company
2016
Ronald BlaylockPfizer
2017
Charles PrinceJohnson Johnson
2006
Yukio ArimaHutchison China MediTech Limite
2015
Srikant DatarNovartis AG
2003
Ann CairnsAstraZeneca PLC
2014
Lynn ElsenhansGlaxoSmithKline plc
2012
Togo WestBristol Myers Squibb Company
2015
Peter WendellMerck Co
2003
Vicki SatoBristol Myers Squibb Company
2017
Dinesh PaliwalBristol Myers Squibb Company
2013

Entity Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company was incorporated in 2012 and is based in North Chicago, Illinois. AbbVie operates under Drug Manufacturers - Major classification in USA and is traded on BATS Exchange. It employs 30000 people.AbbVie (ABBV) is traded on BATS Exchange in USA. It is located in 1 North Waukegan Road and employs 30,000 people. AbbVie is listed under Pharmaceutical Products category by Fama And French industry classification.

AbbVie Leadership Team

Richard Gonzalez, Chairman, CEO and Chairman of Executive Committee
Brian Durkin, Vice President Controller
Thomas Hurwich, Vice President Controller
Frederick Waddell, Independent Director
Robert Alpern, Independent Director
Glenn Tilton, Independent Director
Carlos Alban, Executive VP of Commercial Operations
Robert Michael, Vice President Controller
Henry Gosebruch, Executive Vice President Chief Strategy Officer
Edward Liddy, Independent Director
Brett Hart, Independent Director
William Chase, CFO and Executive VP
William Burnside, Independent Director
Roxanne Austin, Independent Director
Timothy Richmond, Sr. VP of HR
Laura Schumacher, Executive VP of Bus. Devel. and External Affairs, General Counsel and Corporate Secretary
Roy Roberts, Independent Director
Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer
Azita SalekiGerhardt, Senior Vice President - Operations
Edward Rapp, Independent Director
Melody Meyer, Director

Stock Performance Indicators

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Theme Ratings

AbbVie Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for AbbVie and AstraZeneca PLC. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Search macroaxis.com